Preventive Medicine and Screening

• Disease natural history and lead time bias: Disease progresses through phases—subclinical (detectable but asymptomatic) and clinical (symptomatic). Screening detects disease during the subclinical phase, potentially appearing to increase survival time without actually improving outcomes (lead time bias). Screening is only beneficial if detection and early treatment during the subclinical phase improves outcomes compared to waiting for clinical presentation.

• Screening test performance characteristics: Sensitivity (true positive rate; ability to detect disease when present) and specificity (true negative rate; ability to correctly identify those without disease) determine test accuracy. A test with high sensitivity minimizes false negatives (important for serious, treatable conditions), while high specificity minimizes false positives (important to avoid unnecessary treatment and anxiety). Positive predictive value (PPV) and negative predictive value (NPV) depend on disease prevalence and are more clinically relevant than sensitivity/specificity alone.

• Selection bias and screening effectiveness: Screening populations systematically differ from clinical populations—they include asymptomatic individuals, may be self-selected, and often have different risk profiles. Screening is most effective in populations with sufficient disease prevalence, accessible follow-up care, and proven effective treatments available. Conditions with long subclinical phases, high mortality if untreated, and effective early interventions are ideal screening targets.

• Harms of screening: False-positive results cause psychological harm, anxiety, and lead to unnecessary follow-up testing and interventions. Overdiagnosis occurs when screening detects disease that would never have caused clinical symptoms or death (especially important in low-grade cancers and late-life conditions). Screening programs must balance benefits against these harms using number needed to screen (NNS) and number needed to treat (NNT).

• Asymptomatic presentations as screening targets: Individuals presenting for preventive care are typically asymptomatic and may have various risk profiles (age-based, family history-based, lifestyle-based). The clinical encounter involves risk stratification to determine which screening tests are appropriate for individual patients based on evidence-based guidelines (USPSTF, specialty societies).

• Incidental findings during screening: Screening often uncovers unexpected abnormalities unrelated to the target condition (e.g., thyroid nodule on carotid ultrasound). Managing incidental findings requires knowledge of their clinical significance, natural history, and the threshold for further investigation to avoid excessive workup.

• High-risk presentations requiring intensified screening: Certain presentations (family history of early-onset cancer, familial hypercholesterolemia features, unexplained anemia) identify individuals who warrant more aggressive or earlier screening than population-based recommendations. These require clinical judgment and knowledge of inherited disease patterns.

• Screening test interpretation and ROC curves: Sensitivity and specificity define test accuracy; plotting sensitivity against (1-specificity) creates a Receiver Operating Characteristic (ROC) curve. The area under the curve (AUC) quantifies overall test discrimination (0.5 = coin flip; 1.0 = perfect). Moving the threshold for positive/negative results trades sensitivity for specificity; no threshold optimizes both simultaneously.

• Predictive values and Bayes' theorem: PPV = (sensitivity × prevalence) / [(sensitivity × prevalence) + (1-specificity) × (1-prevalence)]. PPV increases with higher disease prevalence, meaning the same test is more useful in high-prevalence populations. NPV decreases with lower disease prevalence. These calculations illustrate why screening low-prevalence populations produces many false positives.

• Screening guideline interpretation: Major guideline-making organizations (USPSTF grades A/B = recommend; C = individualize; D = do not recommend; I = insufficient evidence) base recommendations on systematic reviews and cost-effectiveness analysis. Grade A and B recommendations are appropriate for routine screening; Grade I recommendations require shared decision-making; Grade D recommendations should generally be avoided. Knowing major screening recommendations is high-yield for boards.

• Likelihood ratios and test interpretation: Positive likelihood ratio (LR+) = sensitivity / (1-specificity) describes how much a positive test increases pretest probability. Negative likelihood ratio (LR-) = (1-sensitivity) / specificity describes how much a negative test decreases pretest probability. LR+ > 10 or LR- < 0.1 represent significant changes in probability.

• Primary prevention interventions: These reduce disease incidence in healthy populations. Examples include vaccination (preventing infectious diseases), counseling on lifestyle modification (diet, exercise, smoking cessation), and environmental interventions (water fluoridation). Cardiovascular risk reduction through statins (even in asymptomatic individuals with elevated calculated risk) represents evidence-based primary prevention. Aspirin for primary prevention has limited evidence in current guidelines—generally not recommended for low-risk individuals due to bleeding risk.

• Secondary prevention—screening recommendations by condition:
• Cardiovascular disease: Lipid screening (total cholesterol, LDL, HDL) in all adults ≥20 years; blood pressure screening at every visit; 10-year ASCVD risk calculation using pooled cohort equations guides statin therapy initiation
• Cancer screening: Cervical cancer (Pap/HPV testing age 21-65), breast cancer (mammography age 40-50+ depending on risk; consider earlier with family history), colorectal cancer (age 45-50 to 75; colonoscopy, FIT, or Cologuard), prostate cancer (PSA—individualized discussion age 40-70 with shared decision-making due to overdiagnosis concerns)
• Diabetes: Fasting glucose, A1C, or 2-hour glucose tolerance test in asymptomatic adults ≥45 years or those with risk factors; screening detects prediabetes and diabetes earlier, though cardiovascular benefits of early detection are mixed
• Infectious diseases: TB (tuberculin skin test or IGRA for high-risk groups), syphilis (RPR/VDRL in pregnancy and high-risk groups), HIV (recommended for all 13-64 years), hepatitis B and C (risk-based screening), chlamydia/gonorrhea (sexually active <25 years or risk factors)
• Thyroid disease: TSH screening controversial—USPSTF recommends against routine screening in asymptomatic adults; consider in pregnancy, elderly, or those with symptoms

• Tertiary prevention and management of screening findings: Once disease is identified through screening, management aims to prevent complications. Examples include controlling blood pressure and cholesterol after detection (preventing MI/stroke), managing detected diabetes (preventing complications), and treating precancerous lesions (preventing cancer progression). Anticoagulation in detected atrial fibrillation (preventing stroke) represents tertiary prevention identified through opportunistic screening.

• Special populations and individualized screening:
• Pregnant women: Expanded screening for gestational diabetes (24-28 weeks), preeclampsia risk factors, infections (syphilis, HIV, hepatitis B, Group B Streptococcus)
• Elderly (≥65 years): Balance screening benefits against life expectancy; colonoscopy screening reasonable up to age 75-85 if not previously screened; mammography benefits decline with age; osteoporosis screening (DEXA) in all women ≥65, men ≥70
• High-risk individuals: Family history of hereditary cancer syndromes may warrant genetic testing and surveillance (BRCA1/2, Lynch syndrome, familial adenomatous polyposis)

• False-positive results and cascade of harm: Abnormal screening test results frequently require

Test characteristics — the classic trap

• Sensitivity and specificity are properties of the test, unchanged by prevalence; PPV and NPV move with prevalence. The stem that screens a low-prevalence population and asks "why so many false positives?" is testing exactly this.
• SnNout / SpPin: a highly Snsitive test, when Negative, rules out; a highly Specific test, when Positive, rules in. Screening favors sensitivity; confirmation favors specificity.
• Single best next step after a positive screen is a confirmatory diagnostic test, never initiation of treatment (positive HIV antigen/antibody screen → HIV-1/2 differentiation immunoassay). For syphilis, the confirmatory step depends on which assay came first: the traditional algorithm is nontreponemal (RPR/VDRL) → treponemal test, while the reverse-sequence algorithm now widely used in US labs is treponemal EIA/CIA → RPR → TP-PA if discordant.

Biases examiners love

• Lead-time bias: survival appears longer only because diagnosis was earlier. Length-time bias: screening preferentially catches indolent, slow-growing tumors. Overdiagnosis is the extreme of length-time bias. The tell: improved 5-year survival without improved disease-specific mortality. Mortality (ideally from a randomized trial), not survival time, is the outcome that demonstrates screening benefit; all-cause mortality is the most bias-resistant endpoint, since disease-specific mortality can be distorted by cause-of-death misattribution and by deaths from screening or treatment complications.

Guideline facts most likely to be asked

• USPSTF Grade D means do not screen — routine PSA-based screening in men ≥70 is Grade D. Distinguish this from screening for thyroid dysfunction (TSH) in nonpregnant asymptomatic adults, which is an I statement (insufficient evidence), and screening for thyroid cancer by neck palpation/ultrasound in asymptomatic adults, which is Grade D.
• USPSTF colorectal cancer screening begins at 45; cervical cytology begins at 21 regardless of sexual debut or HPV vaccination; one-time AAA ultrasound in men 65–75 who have ever smoked.
• Low-dose CT for lung cancer (USPSTF): adults 50–80 with a 20 pack-year history who currently smoke or quit within 15 years.
• Statins for primary prevention (USPSTF Grade B; consistent with ACC/AHA cholesterol guidance): adults 40–75 with a risk factor and elevated calculated 10-year ASCVD risk. Aspirin is no longer routine primary prevention — bleeding offsets benefit, especially in older adults.

Vaccination distractors

• Live attenuated vaccines (MMR, varicella, LAIV) are contraindicated in pregnancy and severe immunocompromise (ACIP). Household contacts may still be vaccinated.
• Tdap in every pregnancy, preferably at 27–36 weeks (earlier part of the window optimizes transplacental antibody transfer), for neonatal pertussis protection (ACIP/ACOG).